Enhanced peritoneal membrane plasmapheresis
First Claim
1. A method for removing plasma components from a patient, the method comprising serial instilling and draining of a first physiologic solution with added vasodilator drug, in the patient'"'"'s peritoneal cavity followed by serial instilling and draining of a second physiologic solution with added vasoconstrictor drug in the patient'"'"'s peritoneal cavity.
1 Assignment
0 Petitions
Accused Products
Abstract
The method of treatment called peritoneal membrane plasmapheresis for removal of plasma proteins is enhanced by specification of a sequence of two or three solutions for instilling into and draining from the peritoneal cavity. Solution 1 contains a vosodilator, solution 3 contains no vasoactive drug, and solution 2 contains a vasoconstrictor. Choice of the sequence of solutions to be instilled and drained according to the claimed methods results in sustained opening of peritoneal membrane pores and substantially elevated rates of plasma protein removal, avoiding the problem of declining rates due to local tissue compensatory mechanisms which are observed when only solution 1 is used. Resulting protein removal rates in an anticoagulated patient compare favorably with those attainable with extracorporeal phasmapheresis. An analogous process may be carried out to increase the pore size of any biological membrane accessible to the solutions.
44 Citations
43 Claims
- 1. A method for removing plasma components from a patient, the method comprising serial instilling and draining of a first physiologic solution with added vasodilator drug, in the patient'"'"'s peritoneal cavity followed by serial instilling and draining of a second physiologic solution with added vasoconstrictor drug in the patient'"'"'s peritoneal cavity.
-
4. A method of removing plasma components from a patient'"'"'s circulating blood using first and second physiologic solutions, the method comprising the steps:
-
instilling a first physiologic solution with added vasodilator drug into a patient'"'"'s peritoneal cavity, said vasodilator drug being in an amount effective to increase passage of plasma components into the solution; allowing the first solution to remain in the peritoneal cavity for a first dwell time sufficient to remove plasma components from the patient'"'"'s circulating blood; draining the first solution from the peritoneal cavity; instilling a second physiologic solution with added vasoconstrictor drug into the patient'"'"'s peritoneal cavity, said vasoconstrictor drug being in an amount effective to prevent material reduction in rate of removal of plasma components from the patient'"'"'s circulating blood; allowing the second solution to remain in the peritoneal cavity for a second dwell time sufficient to effect removal of plasma components from the patient'"'"'s circulating blood; and draining the second solution from the peritoneal cavity. - View Dependent Claims (35, 36, 37, 38, 39, 40, 41, 42, 43)
-
Specification